Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech News St. Vincent & Grenadines.
Press releases published on August 11, 2025
New U.S. Politics Today Op-ed Says VOA Editorials Now Back Trump’s Political Agenda
WASHINGTON , DC, UNITED STATES, August 11, 2025 /EINPresswire.com/ -- For several decades, Voice of America has been a staple international multimedia broadcaster, known for promoting freedom and democracy in its reporting of news worldwide. But since …
John Kennedy FitzGerald Increases Ownership in Greenhawk Resources Inc. and Announces Leadership Changes
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenhawk Resources Inc. (“Greenhawk” or the "Company") (CSE: GRHK) announces John Kennedy FitzGerald (“FitzGerald”), of Toronto, Ontario announces that on Friday, August 8, 2025 he acquired in part through the …
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, …
Swift Navigation and Taiwan Mobile Partner to Unlock Autonomy and Automation with Centimeter-Accurate Positioning
SAN FRANCISCO and TAIPEI, Taiwan, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Swift Navigation, the leader in centimeter-accurate positioning for vehicle autonomy, robotics, and precision logistics, and Taiwan Mobile, one of Taiwan’s leading telecommunications …
Microvast Reports Second Quarter 2025 Financial Results
Record Q2 revenue of $91.3 million, up 9.2% year over year Gross margin increased from 32.5% to 34.7%, a 2.2 percentage point improvement year over year STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Microvast Holdings, Inc. (NASDAQ:MVST) (“Microvast” …
Draganfly Announces Second Quarter Results of 2025 with 37% Increase in YoY Product Sales
Vancouver, BC., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce its second quarter …
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ …
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC …
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million private investment in public equity …
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as …
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related …
Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights
FDA PDUFA goal date of August 15, 2025, for TNX‑102 SL for fibromyalgia: if approved by FDA, TNX‑102 SL would be the first new drug for fibromyalgia in more than 16 years In June 2025, the Company was added to the Russell 3000® and Russell 2000® Indexes …
3D Systems Reports Second Quarter 2025 Financial Results
ROCK HILL, S.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the second quarter ended June 30, 2025. Revenue of $95 million led by double-digit growth in Medical Technology and Aerospace …
Microchip Technology to Present at the KeyBanc Technology Leadership Forum
CHANDLER, Ariz., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the Mizuho 2025 Technology …
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China Granted orphan drug designation from the European Medicines Agency (EMA) for amezalpat for the treatment of patients …
PubMatic Announces Second Quarter 2025 Financial Results
Delivered revenue and adjusted EBITDA ahead of guidance; Revenue from omnichannel video, including CTV, grew 34% year-over-year and was 41% of total revenue; CTV revenue grew over 50% year-over-year; Supply Path Optimization represented 55%+ of total …
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
Reiterating timelines for FDA submission in 2025 Transplant clinical trial has attracted leading transplant hospitals Booked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, …
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today …
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025
WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results …